e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Profile of selected cytokines in serum and in BAL-fluid in patients with cryptogenic organising pneumonia before and after 3 months of calrithromycin treatment
E. Radzikowska, E. Wiatr, A. Rozy, R. Langfort, P. Rudzinski, A. Jarzemska, J. Chorostowska (Warsaw, Poland)
Source:
Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease
Session:
Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease
Session type:
E-Communication Session
Number:
5230
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Radzikowska, E. Wiatr, A. Rozy, R. Langfort, P. Rudzinski, A. Jarzemska, J. Chorostowska (Warsaw, Poland). Profile of selected cytokines in serum and in BAL-fluid in patients with cryptogenic organising pneumonia before and after 3 months of calrithromycin treatment. Eur Respir J 2010; 36: Suppl. 54, 5230
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Clinical analysis of 25 subjects with biopsy-proven cryptogenic organizing pneumonia
Source: Annual Congress 2007 - Clinical aspects of idiopathic pulmonary fibrosis
Year: 2007
Serum KL-6 elevation related with severity in patients with pneumocystis pneumonia
Source: Annual Congress 2011 - Infection in the immunocompromised host: infrequent aetiologies
Year: 2011
Serum levels of IL-6 in severe community-acquired pneumonia
Source: Annual Congress 2010 - Pulmonary infections and sepsis
Year: 2010
Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients
Source: International Congress 2015 – Immunodepression and severe pneumonia
Year: 2015
Levels of IL-8 and IL-10 in the serum of blood of patients with nosocomial pneumonia at the abdominal sepsis
Source: Eur Respir J 2005; 26: Suppl. 49, 189s
Year: 2005
The clinical significance of serum and bronchoalveoalr lavage inflammatory cytokine in patients with acute respiratory failure due to severe community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 347s
Year: 2006
Serum KL-6 level is increased in patients with
pneumocystis
pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 101s
Year: 2006
Clinical significance of serum CA 15-3 in patients with idiopathic interstitial pneumonias
Source: Annual Congress 2007 - Interstitial lung disease: diagnostic and therapeutic novelties
Year: 2007
The diagnostic value of serum soluble CD 14 and IL-10 levels in newly diagnosed pulmonary tuberculosis patients and the relationship with disease extensity
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
Systemic cytokine response in patients with community-acquired pneumonia
Source: Eur Respir J 2011; 37: 1431-1438
Year: 2011
Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia
Source: Eur Respir J 2008; 32: 726-732
Year: 2008
Systemic cytokine levels in community-acquired pneumonia and their association with disease severity
Source: Eur Respir J 2002; 20: 990-995
Year: 2002
Local and systemic cytokine profiles in patients with non-severe and severe community-acquired pneumonia
Source: Annual Congress 2012 - Viral infections and rare respiratory infections
Year: 2012
Comparison of inflammatory response biomarkers to predict complications in hospitalized patients with community-acquired pneumonia
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
The non-responding pneumonia
Source: Annual Congress 2005 - Difficult infections in the respiratory patient
Year: 2005
Serum vitamin C level in patients with acute pneumonia and in COPD patients before and after therapy
Source: Eur Respir J 2006; 28: Suppl. 50, 38s
Year: 2006
Serum procalcitonin concentrations in children with pulmonary tuberculosis, tuberculous infection and lober pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 176s
Year: 2003
An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept